8 patents
Utility
Methods of treating pruritic disease with IL-31 monoclonal antibodies
3 Jan 23
The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
Kent Bondensgaard, Roland Beckmann
Filed: 30 Mar 20
Utility
Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions
26 Apr 22
The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
Janine M. Bilsborough
Filed: 28 Feb 20
Utility
Nucleic acid molecules encoding humanized IL-31 monoclonal antibodies
4 May 20
The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
Kent Bondensgaard, Roland Beckmann
Filed: 25 Apr 18
Utility
Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases
4 May 20
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F.
Stephen R. Jaspers, Scott R. Presnell
Filed: 14 Jun 18
Utility
Methods of treating skin disorders using anti-IL-31RA antibodies
6 Apr 20
The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
Janine M. Bilsborough
Filed: 22 Apr 18
Utility
Soluble hybrid Fcγ receptors and related methods
24 Feb 20
Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation.
Carl W. Birks, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
Filed: 20 Apr 17
Utility
Treating inflammation with IL-17/IL-23 bispecific antibodies
17 Feb 20
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23.
Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
Filed: 7 May 18
Utility
Use of IL-31 monoclonal antibodies for treating pruritus
7 Oct 19
Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided.
Anthony W. Siadak, Janine M. Bilsborough, Shirley A. Rene
Filed: 13 Dec 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first